Fig. 2

Platelet VEGF levels in healthy individuals and cancer patients. Both groups of subjects included women and men, and patients were those individuals recruited for CENTAURO and CENTAURO-2 clinical trials. a Platelet VEGF levels in healthy individuals and platelet VEGF levels in cancer patients before vaccination (week 0). b Platelet VEGF levels in healthy individuals and platelet VEGF levels after vaccination (week 13). Horizontal bars represent the median values of platelet VEGF. c Platelet VEGF levels in cancer patients before and after vaccination. The variation (Δ) of platelet VEGF levels, expressed in percentages, was calculated using Eq. 2 as described in “Methods”. Blue symbols represent patients with VEGF reduction (Δ ≤ − 30%), green symbols represent patients with VEGF stability (− 30% < Δ < 30%), and red symbols represent patients with VEGF increase (Δ ≥ 30%). Discontinued lines represent the range (maximum and minimum) of platelet VEGF obtained from healthy individuals. Statistical significance was considered as p < 0.05. ns non-significant